A growing body of literature suggests that STAG2 deletion or loss-of-function truncating mutations sensitize cancer cells to PARP inhibitors, including olaparib, rucaparib, and veliparib, although to date these studies have not been conducted in bladder cancer [2, 16, 17]. The gene discussed is STAG2; the disease is urinary bladder cancer.